147 related articles for article (PubMed ID: 21439018)
1. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
Schadendorf D
J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
[No Abstract] [Full Text] [Related]
2. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
3. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
4. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
5. BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.
Richtig E; Schrama D; Ugurel S; Fried I; Niederkorn A; Massone C; Becker JC
Br J Dermatol; 2013 Feb; 168(2):428-30. PubMed ID: 22775439
[No Abstract] [Full Text] [Related]
6. BRAF inhibitors: research accelerates in wake of positive findings.
Brower V
J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
[No Abstract] [Full Text] [Related]
7. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
[TBL] [Abstract][Full Text] [Related]
8. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
9. Targeting metastatic melanoma.
Flaherty KT
Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
[TBL] [Abstract][Full Text] [Related]
10. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1.
Skorokhod A; Capper D; von Deimling A; Enk A; Helmbold P
J Am Acad Dermatol; 2012 Sep; 67(3):488-91. PubMed ID: 22890732
[No Abstract] [Full Text] [Related]
11. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
12. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
Ezra N; Hamid O; Behroozan D
Dermatol Surg; 2012 Jul; 38(7 Pt 1):1086-90. PubMed ID: 22563699
[No Abstract] [Full Text] [Related]
13. Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies AM; Long GV
Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
[TBL] [Abstract][Full Text] [Related]
14. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
15. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
Nathan P; Sharma A; Lorigan P
Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
[No Abstract] [Full Text] [Related]
16. Selumetinib increases the efficacy of first-line dacarbazine.
Cancer Discov; 2013 Jul; 3(7):OF16. PubMed ID: 23847359
[TBL] [Abstract][Full Text] [Related]
17. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
Sondak VK; Smalley K
Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
[No Abstract] [Full Text] [Related]
18. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
19. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.
Falanga A; Marchetti M; Massi D; Merelli B; Verzeroli C; Russo L; Rulli E; Tondini C; Legramandi L; Nassini R; Scatena C; De Logu F; Cattaneo L; Mandalà M
J Am Acad Dermatol; 2016 Jun; 74(6):1254-1256.e4. PubMed ID: 27185428
[No Abstract] [Full Text] [Related]
20. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]